Silverstream Medical, an Israeli company established in 2001 and reestablished in November 2021 after a successful management buyout, focused on eliminating surgical site infections (SSIs), a major cause of hospital readmissions and mortality. SSIs affect 5% of surgeries annually in the US alone, with even higher rates globally. Silverstream Medical is a leading medical device company dedicated to developing and commercializing innovative solutions for the prevention of SSI and wound care, offering a range of patented products. The company operates globally with a US subsidiary, Silverstream Medical LLC, and a robust distribution network spanning 22 countries, adhering to international quality standards including ISO 13485:2016 certification.
Our flagship product, Silverstream, is an FDA-approved solution with nearly 500,000 successful treatments and is commercially available in multiple countries. It actively prevents infections by destroying biofilm and inhibiting bacteria growth. We've proven our effectiveness in post-operative care, for which we currently have FDA approval for our innovative silver-based solution, and are now expanding into the in-surgical SSI market, projected to reach $7.5 billion by 2030, aiming to prevent infections in real-time during surgical procedures. We are pursuing clinical trials to demonstrate the safety and efficacy of our technology in this area.
The SilverStream solution is set to become the dominant global choice for surgical disinfection, revolutionizing surgical outcomes worldwide. With this expansion, we project revenues exceeding tens of millions of USD within the next three years. Driven by a vision of a world free from SSI-related complications and a commitment to improving patient outcomes and optimizing healthcare resources, Silverstream Medical is poised to become a global leader in the fight against surgical site infections.